Reply to Gautret et al: hydroxychloroquine sulfate and azithromycin for COVID-19: what is the evidence and what are the risks?
Julian D. Machiels, Chantal P. Bleeker‐Rovers, Rob ter Heine, Janette Rahamat–Langendoen, Quirijn de Mast, Jaap ten Oever, Teun Bousema, Reinout van Crevel, Heiman Wertheim
Topics & Concepts
HydroxychloroquineAzithromycinCoronavirus disease 2019 (COVID-19)MedicinePandemic2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Clinical trialIntensive care medicineVirologyInternal medicineOutbreakBiologyMicrobiologyDiseaseAntibioticsInfectious disease (medical specialty)COVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 ResearchDermatological and COVID-19 studies